Results 181 to 190 of about 1,314 (191)

Efficacy and safety of intravitreal Fluocinolone Acetonide microimplant (ILUVIEN®) in patients with chronic diabetic macular edema: 1 year follow-up

European Journal of Ophthalmology, 2021
Purpose: Evaluate the efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide (FAc) micro implant in patients with chronic diabetic macular edema (cDME). Methods: Prospective study recruiting subjects with cDME. Inclusion criteria: cDME for at
F. Pacella, E. Pacella, E. Trovato Battagliola, M. Malvasi, S. Z. Scalinci, P. Turchetti, M. Salducci, Luca Lucchino, L. Arrico   +8 more
semanticscholar   +1 more source

The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®) in diabetic macular oedema in a multi-ethnic inner-city population

European Journal of Ophthalmology, 2020
Purpose: The purpose of this study is to report the long-term efficacy and safety of 0.19 mg fluocinolone acetonide intravitreal implant (ILUVIEN®) in pseudophakic eyes with diabetic macular oedema in a multi-ethnic patient cohort.
G. Panos, N. Arruti, S. Patra
semanticscholar   +1 more source

Iluvien^™: a new sustained delivery technology for posterior eye disease

Expert Opinion on Drug Delivery, 2008
Iluvien (fluocinolone acetonide intravitreal insert, Alimera Sciences, Inc.), a novel injectable intravitreal insert, is being studied to deliver a very low dose of a corticosteroid to the retina for up to 3 years as a treatment for diabetic macular edema.
Frances E, Kane, Judith, Burdan, Antonio, Cutino, Kenneth E, Green   +3 more
openaire   +2 more sources

Fluocinolone Acetonide Intravitreal Implant (Iluvien®)

Drugs, 2013
Fluocinolone acetonide intravitreal implant (Iluvien®) is an injectable, non-erodible, corticosteroid implant that is approved in several European countries for the treatment of chronic diabetic macular oedema (DMO). In analyses of two multinational trials in patients with DMO previously treated with macular laser photocoagulation, fluocinolone ...
openaire   +2 more sources

Fluocinolone acetonide (Iluvien) extended-release intravitreal implant for diabetic macular edema

Expert Review of Ophthalmology, 2014
Fluocinolone acetonide (FAc) is a corticosteroid used in the FAc implant, a novel drug-delivery device currently approved in Europe but not yet approved in the USA. The drug delivery system for FAc implant allows a sustained delivery in a more posterior location in the eye and can be delivered in an outpatient setting.
Michelle V Carle, Thomas G Chu, David S Boyer   +2 more
openaire   +1 more source

[Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].

Journal francais d'ophtalmologie, 2016
Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN(®), which is a ...
G, Soubrane, F, Behar-Cohen
openaire   +1 more source

Iluvien monotherapy for diabetic macular oedema in vitrectomised and non‐vitrectomised eyes: one year data

Acta Ophthalmologica, 2016
PurposeTo assess the effectiveness of the Fluocinolone intravitreal implant (Iluvien) in patients with diabetic macular oedema (DMO) following previous pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). The data from vitrectomised eyes are compared with a consecutive group of non‐vitrectomised eyes with DMO who received the ...
A. Hawrami, H. Laviers, S. Patra, H. Zambarakji   +3 more
openaire   +1 more source

Intravitreal fluocinolone acetonide 0.19 mg (Iluvien®) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients

Graefe's Archive for Clinical and Experimental Ophthalmology, 2021
A. Studsgaard, K. Clemmensen, M. S. Nielsen   +2 more
semanticscholar   +1 more source

SMC accepts use of Iluvien

PharmacoEconomics & Outcomes News, 2014
openaire   +1 more source

Iluvien looking good in France

PharmacoEconomics & Outcomes News, 2013
openaire   +1 more source